Results 141 to 150 of about 116,751 (358)
Use of placebos and post-trial benefits
DST, 2022 Brazilian legislators have not yet enacted any laws regarding the use of placebos and the duties of assistance to research subjects. As a result of this omission, public administrative authorities have to deal with the subject on a regular basis ...
Revista Brasileiro de Doenças Sexualmente Transmissíveis
doaj
Psychometric study of children with learning problems and 14-6 positive spike EEG patterns, treated with ethosuximide (Zarontin) and placebo. [PDF]
, 1968 W. Lynn Smith +2 more
openalex +1 more source
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
Arthritis &Rheumatology, EarlyView.Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler +34 more
wiley +1 more source
Active-Controlled Trial Design for HIV Prevention Trials with a Counterfactual Placebo [PDF]
arXivIn the quest for enhanced HIV prevention methods, the advent of antiretroviral drugs as pre-exposure prophylaxis (PrEP) has marked a significant stride forward. However, the ethical challenges in conducting placebo-controlled trials for new PrEP agents against a backdrop of highly effective existing PrEP options necessitates innovative approaches ...
arxiv
Chlorpromazine, Trifluoperazine and Placebo with Long-Term Mental Hospital Patients [PDF]
, 1962 W. H. Coons, B. A. Boyd, John White
openalex +1 more source
Arthritis &Rheumatology, EarlyView.Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin +11 more
wiley +1 more source
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Arthritis &Rheumatology, EarlyView.Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley +1 more source
Dietary Supplement Labeling: Cognitive Biases, Market Manipulation & Consumer Choice [PDF]
, 2014 There exists increasing concern that the Dietary Supplements Health and Education Act (DSHEA) has proven ineffective. Much of the concern regards the disparity in legislative treatment between dietary supplements, foods, and pharmaceutical drugs. Namely,
McCann, Michael
core +1 more source